<DOC>
	<DOCNO>NCT03051386</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity VEE vaccine , Live , Attenuated , dry TC-83 , NDBR 102 , Lot 4 , Run 3 , collect data incidence occupational VEE virus infection vaccinate personnel .</brief_summary>
	<brief_title>Safety Immunogenicity Venezuelan Equine Encephalomyelitis Vaccine Healthy Adults</brief_title>
	<detailed_description>This protocol replace NCT00582504 . The study population consist USAMRIID qualify extramural participant risk exposure VEE virus . This study perform USAMRIID SIP Clinic . This open-label study represent continuation previous research conduct USAMRIID . Subjects vaccinate 0.5 mL VEE vaccine , Live , Attenuated TC-83 , NDBR 102 , Lot 4 , Run 3 subcutaneously upper outer aspect triceps region . Subjects contact follow day weekly 4 week assess adverse event .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Encephalomyelitis</mesh_term>
	<mesh_term>Encephalomyelitis , Venezuelan Equine</mesh_term>
	<mesh_term>Encephalomyelitis , Equine</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Be 1865 year old time consent . 2 . Have VEE virus PRNT80 &lt; 1:10 . 3 . If female childbearing potential , must agree serum pregnancy test day vaccine administration . ( Exception : documented hysterectomy â‰¥ 3 year menopause . ) The result must negative . Females must agree become pregnant 3 month receipt vaccination . 4 . Be consider risk exposure VEE virus submit Request IND Vaccines VEE vaccine . 5 . Sign date approve informed consent document HIPAA Authorization . 6 . Have chart : medical history ( include concomitant medication ) within 60 day plan first administration vaccine physical examination laboratory test within 1 year previous chest radiograph result electrocardiogram 7 . Be medically clear participation investigator . Examinations test may repeat discretion PI . 8 . Be willing return followup visit . 9 . Agree report AEs may may associate administration vaccine least 28 day administration agree report SAEs ( example , result hospitalization ) duration subject 's participation study . 10 . Agree defer blood donation 1 year receipt vaccine . 1 . Have receive VEE vaccine . 2 . Have family history ( first degree relative ) diabetes mellitus ( type ) , personal family history gestational diabetes , confirm elevate fast serum glucose test ( &gt; 125 mg/dL ) , hemoglobin A1c &gt; 5.6 % . ( At principal investigator 's discretion , subject may participate family history diabetes late onset elderly parent . ) 3 . Have clinically significant abnormal laboratory result ( include evidence hepatitis C , hepatitis B carrier state ) elevate liver function test ( two time normal range discretion PI ) . 4 . Have personal history immunodeficiency receive treatment immunosuppressive medication , systemically administer glucocorticoid ( eg prednisone ) within 1 month plan administration vaccine immunosuppressive therapy within 6 month plan administration vaccine . Other immunosuppressive therapy include cancer chemotherapeutic agent , drug prevent transplant rejection , interferon , monoclonal antibody , protein kinase inhibitor , methotrexate , TNF ( tumor necrosis factor ) inhibitor , drug determine immunosuppressive PI . Current administration topical , inhalational , intranasal glucocorticoid exclude . 5 . Have confirm HIV infection ( antibody positivity ) . 6 . Have positive pregnancy test breastfeed female . 7 . Have know allergy component vaccine : Neomycin sulfate Guinea pig heart cell Streptomycin Human serum albumin 8 . History serious allergic reaction guinea pig guinea pig product . ( Subjects know allergy guinea pig evaluate . The vast majority individual allergic guinea pig allergic dander animal . An individual past serious allergic reaction guinea pig exclude . ) 9 . Have administration another vaccine investigational product within 28 day VEE vaccination . 10 . Have unresolved AE result previous immunization . 11 . Have medical condition , judgment PI , would impact subject safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>